Cellular Imaging and Molecular Pathology

细胞成像和分子病理学核心的作用是为项目中的研究人员提供支持 Project Grant通过提供一套专门的分子生物学和体内最先进的分子 影像分析。这些共同构成了有效评估疾病状态的必要工具， 患者和动物模型对治疗的反应的分子基础和分析 细胞种群的活体命运。此核心提供的服务超出常规范围 临床前研究和标准临床护理。此核心为监控以下项目提供分子测试 治疗结果，检测早期疾病复发和最低程度的疾病状态。快速、定量 对实验疗法的评估对于加速和准确分析潜力是必要的。 功效。我们已经开发了分子成像工具，用于在活体动物模型中进行此类分析 将用于研究和优化本计划中提出的治疗方法。一种成熟的小动物 斯坦福大学的成像核心资源为这些调查和 将继续针对特定的程序性应用程序改进方法，并向临床成像迈进 战略。体内分子成像将用于指导体外检测，以获得更有意义的结果 综合分析。利用新的生物发光标记的体内成像策略，允许 疾病负担的定量、非侵入性检测和细胞种群的跟踪将用于 项目3、4、5、7和8.疾病特有的染色体易位或转录的分子测试 将为项目1、2和8提供关于白血病和淋巴瘤标本的产品。量化 将使用TaqMan化学方法进行最小残留疾病的评估，以实现可靠的评估 对临床标本的疾病反应和潜在复发的预测。的集中表现 这个核心的分子程序将避免程序中的重复工作，并确保及时、高效 和始终如一的高质量结果。这种体内和体外分析的结合加强了 通过提供更多数据并集中对临床和临床前样本进行直接评估进行的研究 核心。

The role of the Cellular Imaging and Molecular Pathology Core is to support investigators in the Program Project Grant by providing a set of dedicated molecular biological and state-of-the-art in vivo molecular imaging analyses. Together these comprise the necessary tools for effective assessment of disease states, the molecular basis of response to therapy both in patients and in animal models and the analysis of the in vivo fate of cellular populations. The services provided by this Core are those that extend beyond routine preclinical studies and standard clinical care. This Core provides molecular testing for projects that monitor treatment outcomes, detect early disease recurrence and minimal disease states. Rapid and quantitative assessment of experimental therapies is necessary for accelerated and accurate analyses of potential efficacy. We have developed molecular imaging tools for such analyses in living animal models and these will be used to study and optimize the therapies proposed in this program. An established Small Animal Imaging Core Resource at Stanford provides the instrumentation and expertise for these investigations and will continue to refine the methods for specific programmatic applications and move toward clinical imaging strategies. In vivo molecular imaging will be used to direct the ex vivo assays for more meaningful comprehensive analyses. In vivo imaging strategies utilizing novel bioluminescent markers which allow for the quantitative, noninvasive detection of disease burden and tracking of cellular populations will be used in Projects 3, 4, 5, 7 and 8. Molecular testing for disease specific chromosomal translocations or transcription products will be performed for Projects 1, 2 and 8 on leukemia and lymphoma specimens. Quantitative assessment of minimal residual disease will be performed using TaqMan chemistry for a robust assessment of disease response and potential recurrence on clinical specimens. The centralized performance of the molecular procedures by this Core will avoid duplication of efforts in the program and ensure timely, efficient and consistently high quality results. This combination of in vivo and ex vivo analyses strengthens the studies by providing more data and directed evaluation of clinical and preclinical specimens in a centralized core.